Category: Press Releases

Diagnostics, Press Releases

XPhyto Signs German Distribution, Storage and Logistics Agreement for 25-Minute COVID-19 PCR Test

Apr 21, 2021

XPhyto has entered into an agreement with an established German pharmaceutical wholesaler and service provider for the distribution, storage and logistics of XPhyto's diagnostic products...

Continue Reading

Press Releases

XPhyto adds Top-Level Executive Talent to its Global Operations

Apr 20, 2021

XPhyto announces the appointment of Mr. Wolfgang Probst as the Chief Operations Officer (COO) of XPhyto and the addition of Mr. Manfred Buchberger as the...

Continue Reading

Diagnostics, Press Releases

XPhyto announces European Approval for 25 Minute COVID-19 PCR Test

Mar 18, 2021

CE Mark received for in vitro diagnostic (IVD) test for the detection of SARS-CoV-2Rapid results with ease of use - single 20-minute PCR cycle plus...

Continue Reading

Diagnostics, Press Releases

XPhyto Partner Receives ISO Certification for 25-Minute COVID-19 RT-PCR Test

Mar 10, 2021

Vancouver, Canada (March 10, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), and its exclusive German diagnostics development partner,...

Continue Reading

Press Releases

XPhyto Completes Corporate Rebranding and Launches New Website

Mar 4, 2021

Vancouver, Canada (March 4, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company...

Continue Reading

Press Releases

Xphyto provides updated comments on promotional and marketing activity

Feb 26, 2021

VANCOUVER, British Columbia – February 26, 2021 – XPhyto Therapeutics Corp. (CSE: XPHY; OTC: XPHYF; FSE: 4XT) (“XPhyto” or the “Company”) at the request of...

Continue Reading

Diagnostics, Press Releases

XPhyto Places First Order For 25-Minute COVID-19 RT-PCR Tests

Feb 24, 2021

Vancouver, Canada (February 24, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that it has...

Continue Reading

Diagnostics, Press Releases

XPhyto Builds Commercial Team To Launch 25-Minute COVID-19 RT-PCR Test

Feb 22, 2021

Vancouver, Canada (February 22, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company...

Continue Reading

Diagnostics, Press Releases

XPhyto European CE-IVD Application For 25-Minute COVID-19 RT-PCR Test

Feb 16, 2021

Vancouver, Canada (February 16, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), and its exclusive German diagnostics development partner,...

Continue Reading

Press Releases, Psychedelics

XPhyto Adds Mescaline Production To Psychedelic Medicine Programs

Feb 10, 2021

Vancouver, Canada (February 10, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories...

Continue Reading

Press Releases, Psychedelics

XPhyto Announces Psychedelic Pharmaceutical Production Agreement

Feb 3, 2021

Vancouver, Canada (February 3, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories...

Continue Reading

Drug Delivery, Press Releases

XPhyto Announces Drug Formulation Strategy And 2021 Milestones

Jan 28, 2021

Construction of commercial drug manufacturing facility in GermanyFour clinical studies in neurological indications in 2021Development of oral biosensor and contract development & manufacturingPsychedelic transdermal and...

Continue Reading